Biological activity of acyclonucleosides

  • L. A. Agrofoglio
  • S. R. Challand
Chapter

Abstract

The acyclic nucleosides include the most significant group of anti-viral drugs yet discovered, both from the clinical point of view and in commercial value, with annual sales of the order of £1 bn per annum in 1996. The pioneering drug of this group is acyclovir, discovered in 1974, which represented a revolutionary advance over previous forms of therapy for Herpes simplex infections, both as regards efficacy and safety. The investigation and rationalisation of its mode of action opened up new vistas for further research. Nothing better illustrates the pre-eminence of this drug in its field than the fact that it was more than 12 years after its initial commercialisation in 1981 before any competitor was approved for use, both valaciclovir and famciclovir being launched in the mid-1990s. These drugs do however possess disadvantages in that the spectrum of activity and clinical indications arising therefrom are largely confined to Herpes simplex and Varicella zoster infections; it is the desire to address these drawbacks and overcome them which has driven much of the research in the field. Figure 2.1 gives the structures of the compounds of major interest, several of which are now in common use, and all of which are, or have been, under intensive investigation. They will provide the focus for this chapter.

Keywords

Thymidine Kinase Antiviral Agent Feline Immunodeficiency Virus HCMV Infection Human Embryonic Lung 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    For reviews, see: (a) De Clercq, E., Walker, R. T. in Progress in Medicinal Chemistry, Ellis, G. P., West, G. B., eds, Elsevier, New York 1986, 23, chap. 5. (b) Chu, C. K., Cutter, S. J. J. Heterocycl Chem. 1986, 23, 289. (c) Remy, R. J., Secrist, J. A. Nucleosides Nucleotides 1985, 4,411. (d) Hammer, S. M. AIDS 1996,10 (Suppl. 3), S1.(e) Perigaud, C., Gosselin, G., Imbach, J.-L. Ann. Inst. Pasteur 1992, 3, 179. (f) Kulikowski, T. Pharm. World. Sci. 1994, 16, 127. (g) Harnden, M. R. Drugs of the Future 1990, 14, 3407. For review on anti-HSV agents: Alrabiah, F. A., Sacks, S. L. Drugs 1996, 52, 17. For review on anti-herpetic agents: Gough, G., Smith, P. W. Exp. Opin. Ther. Patents 1996, 6, 753.Google Scholar
  2. 2.
    (a) Elion, G. B., Furman, P. A., Fyfe, J. A. et al. J. Proc. Natl. Acad. Sci. USA 1977, 74, 5716. (b) Schaeffer, H. J., Beauchamp, L., De Miranda, P. et al. Nature, 1978, 272, 583. (c) Furman, P. A., Miranda, P., De Clair, M. H. S., Elion, G. B. Antimicrob. Agents Chemother. 1981, 20, 518.CrossRefGoogle Scholar
  3. 3.
    De Clercq, E. in Advances in Drug Research, Testa, B., ed., Academic Press, London, 1988, pp. 1.Google Scholar
  4. 4.
    Richards, D. M., Carmine, A. A., Brogden, R. N. et al. Drugs, 1983, 26, 374.CrossRefGoogle Scholar
  5. 5.
    Shannon, W. M. in Antiviral Agents and Viral Disease of Man, Galasso, G. J., ed., Raven Press, New York 1984, pp. 55.Google Scholar
  6. 6.
    Thin, R. N. Am. J. Med 1988,85, (2A) 3.Google Scholar
  7. 7.
    Field, A. K., Davies, M. E., DeWitt, C. et al. Proc. Natl. Acad. Sci. USA 1983, 80, 4139.CrossRefGoogle Scholar
  8. 8.
    Smee, D. F., Martin, J. C., Verheyden, J. P. H., Matthews, T. R. Antimicrob. Agents Chemother. 1983, 23, 676.CrossRefGoogle Scholar
  9. 9.
    Cheng, Y.-C., Grill, S. P., Dutschman, G. E. et al. J. Biol. Chem. 1983, 258, 12460.Google Scholar
  10. 10.
    Mansuri, M. M., Martin, J. C. in Annual Reports in Medicinal Chemistry, White, R. J., ed., Academic Press, New York 1987, pp. 147.Google Scholar
  11. 11.
    De Miranda, P., Good, S. S. Antiviral Chem. Chemother. 1992, 3, 1.Google Scholar
  12. 12.
    Robins, R. K., Revankar, G. R. in Antiviral Drug Development. A Multidisciplinary Approach, De Clercq, E., Walker, R. T., eds, Plenum Press, New York 1987, pp. 11.Google Scholar
  13. 13.
    Shannon, W. M. in Antiviral Agents and Viral Diseases of Man, Galasso, G. J., ed., Raven Press, New York 1984, pp. 55.Google Scholar
  14. 14.
    Furman, P. A., St. Clair, M. H., Fyfe, J. A. et al. J. Virol. 1979, 32, 72.Google Scholar
  15. 15.
    Good, S. S., Krasny, H. C., Elion, G. B., De Miranda, P. J. Pharmacol. Exp. Ther. 1983, 227, 644.Google Scholar
  16. 16.
    Krenitsky, T. A., Hall, W. W., De Miranda, P. et al. Proc. Natl. Acad. Sci. USA 1984, 81, 3209.CrossRefGoogle Scholar
  17. 17.
    Quinn, R. P., Good, S. S., Gerald, L., Sabatka, J. J. Anal. Biochem. 1983,134, 16.CrossRefGoogle Scholar
  18. 18.
    Selby, P., Powless, R. L., Blake, S. et al. Lancet 1984, 2, 1428.CrossRefGoogle Scholar
  19. 19.
    Spector, T., Jones, T. E., Beacham, L. M. Biochem. Pharmacol. 1983, 32, 2505.CrossRefGoogle Scholar
  20. 20.
    O’Brien, J. J., Campoli-Richards D. M. Drugs, 1989, 37, 233 (Review).CrossRefGoogle Scholar
  21. 21.
    Whitley, R. J., Gnann, J. W. N. Engl. J. Med. 1992, 327, 782 (Review).CrossRefGoogle Scholar
  22. 22.
    Dorsky, D. I., Crumpacker, C S. Ann. Intern. Med. 1987,107, 859 (Review).Google Scholar
  23. 23.
    Estes, J. E., Huang, E.-S. J. Virol. 1977, 24, 13.Google Scholar
  24. 24.
    Meijer, H., Bruggerman, C. A., Dormans, P. H. J., Van Boven, C. P. A. FEMS Microbiol. Lett. 1984, 25, 283.CrossRefGoogle Scholar
  25. 25.
    Nishimaki, J., Miyazawa, K., Gotoh, A. et al. Leukemia Res. 1996, 20, 415.CrossRefGoogle Scholar
  26. 26.
    Boivin, G. Union Med. Can. 1993,122, 31.Google Scholar
  27. 27.
    Field, A. K., Biron, K. K. Clin. Microbiol. Rev. 1994, 7, 1.Google Scholar
  28. 28.
    Drach, J. C in Targets for the Design of Antiviral Agents, De Clercq, E., Walker, R. T., eds, Plenum Press, New York 1984, pp. 231.Google Scholar
  29. 29.
    Coen, D. M. Antiviral Res. 1991, 15, 287.CrossRefGoogle Scholar
  30. 30.
    Collins, P., Darby, G. Rev. Med. Virol. 1991,1, 19.CrossRefGoogle Scholar
  31. 31.
    (a) Burnette, T. C., Harrington, J. A., Reardon, J. E. et al. J. Biol. Chem. 1995, 270, 15827. (b) Easterbrook, P., Wood, M. J. J. Antimicrob. Chemother. 1994, 34, 307. (c) Reusser, P. J. Hosp. Infect. 1996, 33, 235. (d) Beauchamp, L. M., Krenitsky, T. A. Drugs Future 1993, 18, 619. (e) Beutner, K. R., Friedman, D. J., Forszpaniak, C et al. Antimicrob. Agents Chemother. 1995, 39, 1546. (f) Jacobson, M. A. J. Med. Virol 1993, Suppl. 1, 150. (g) Murray, A. B. Antivir. Chem. Chemother. 1995, Suppl. 1, 34. (h) Bodsworth, N. J., Crooks, R. J., Borelli, S. et al. Genitourinary Med. 1997, 73, 110.CrossRefGoogle Scholar
  32. 32.
    (a) Stein, D. S., Graham, N. M., Park, L. P. et al. Ann. Intern. Med. 1994, 121, 100. (b) Fiddian, A. P. Antivir. Agents Chemother. 1995, 6 (Suppl. 1), 51. (c) Wood, M. J. J. Antimicrob. Chemother. 1996, 37 (Suppl. B), 97.Google Scholar
  33. 33.
    (a) Beutner, K. R. Antiviral Res. 1995, 28, 281. (b) Crooks, R. J. Antivir. Chem. Chemother. 1995, 6 (Suppl. 1) 39. (c) Crooks, R. J., Murray, A. Antivir. Chem. Chemother. 1994, 5 (Suppl. 1), 31. (d) Soul-Lawton, J., Seaber, E., On, N. et al. Antimicrob. Agents Chemother. 1995, 39, 2759. (e) Wang, L. H., Schultz, M., Weller, S. et al. Antimicrob. Agents Chemother. 1993, 40, 80. (0 Weller, S., Blum, M. R., Doucette, M. et al. Clin. Pharmacol. Ther. 1993, 54, 595.CrossRefGoogle Scholar
  34. 34.
    Schaeffer, H. J. in Nucleosides, Nucleotides and Their Biological Applications, Rideout, J. L., Henry, D. W., Beacham, L. M., eds, Academic Press, New York 1983, pp. 1.Google Scholar
  35. 35.
    Martin, J. C, Dvorak, C. A., Smee, D. F. et al. J. Med. Chem. 1983, 26, 759.CrossRefGoogle Scholar
  36. 36.
    Ogilvie, K. K., Cheriyan, U. O., Radatus, B. K. et al. Can. J. Chem. 1982, 60, 3005.CrossRefGoogle Scholar
  37. 37.
    Smith, K. O., Galloway, K. S., Ogilvie, K. K., Cheriyan, U. O. Antimicrob. Agents Chemother. 1982, 22, 1206.Google Scholar
  38. 38.
    Smith, K. O., Galloway, K. S., Kenneil, W. L. et al. Antimicrob. Agents Chemother. 1982, 22, 55.CrossRefGoogle Scholar
  39. 39.
    St. Clair, M. H., Miller, W. H., Miller, R. L. et al. Antimicrob. Agents Chemother. 1984, 25, 191.CrossRefGoogle Scholar
  40. 40.
    Robinson, E. A., White, G. Antimicrob. Agents Chemother. 1983, 24, 221.CrossRefGoogle Scholar
  41. 41.
    Ashton, W. T., Karkas, J. D., Field, A. K., Tolman, R. L. Biochem. Biophys. Res. Commun. 1982,108, 1716.CrossRefGoogle Scholar
  42. 42.
    Freitas, V. R., Smee, D. F., Chernow, M. et al. Antimicrob. Agents Chemother. 1985, 28, 240.CrossRefGoogle Scholar
  43. 43.
    (a) Cheng, Y.-C., Huang, E.-S., Lin, J.-C. et al. Proc. Natl. Acad. Sci. USA 1983, 80, 2767. (b) Maudgal, P. C., De Clercq, E., Descamps, J., Missotten, J. Arch. Ophthalmol. 1984,102, 140. (c) Cheng, Y.-C., Grill, S. P., Dutschman, G. E. et al. Antimicrob. Agents Chemother. 1984, 26, 283.CrossRefGoogle Scholar
  44. 44.
    Pass, R. F., Hutto, C., Ricks, R., Cloud, G. A. N. Engl. J. Med. 1986, 314, 1414.CrossRefGoogle Scholar
  45. 45.
    Felsenstein, D., Amici, D. J., Hirsch, M. S. et al. Ann. Intern. Med. 1985,103, 377.Google Scholar
  46. 46.
    Morris, D. J. J. Antimicrob. Chemother. 1988, 21, 519.CrossRefGoogle Scholar
  47. 47.
    Matthews, T., Boehme, R. Rev. Infect. Dis. 1988, 10 (Suppl. 3), S490.CrossRefGoogle Scholar
  48. 48.
    Sullivan, V., Talarico, C L., Stanat, S. C. et al. Nature 1992, 358, 162.CrossRefGoogle Scholar
  49. 49.
    Biron, K. K., Stanat, S. C., Sorrell, J. B. et al. Proc. Natl. Acad. Sci. USA 1985, 82, 2473.CrossRefGoogle Scholar
  50. 50.
    Fraser-Smith, E. B., Eppstein, D. A., Marsh, Y. V., Matthews, T. R. Antiviral Res. 1985, 5, 137.CrossRefGoogle Scholar
  51. 51.
    Fraser-Smith, E. B., Eppstein, D. A., Marsh, Y. V., Matthews, T. R. Antimicrob. Agents Chemother.1984, 25,191.CrossRefGoogle Scholar
  52. 52.
    Frank, K. B., Chiuo, J.-F., Cheng, Y.-C. J. Biol. Chem. 1984, 259, 1566.Google Scholar
  53. 53.
    Fletcher, C V., Balfour, H. H. Drug. Intell. Clin. Pharm. 1989, 23, 5.Google Scholar
  54. 54.
    Biron, K. K. Transplant. Proc. 1991,162, 23.Google Scholar
  55. 55.
    Sasaki, T., Okayama, A., Eizuru, Y. et al. Intern. Med. 1997, 36, 375.CrossRefGoogle Scholar
  56. 56.
    Biron, K. K., Fyfe, J. A., Stanat, S. C et al. Proc. Natl. Acad. Sci. USA 1986, 83, 8769.CrossRefGoogle Scholar
  57. 57.
    Stanat, S. C., Reardon, J. E., Erice, A. et al. Antimicrob. Agents Chemother. 1991, 35, 2191.CrossRefGoogle Scholar
  58. 58.
    Okkleberry, K. M., Warren, R. P., Smee, D. F. Antiviral Res. 1997, 35, 83.CrossRefGoogle Scholar
  59. 59.
    Winkelmann, E., Winkler, I., Roily, H. et al. Drug. Res. 1988, 38, 1545.Google Scholar
  60. 60.
    Winkler, I., Winkelmann, E., Scholl, T. et al. Antiviral Res. 1990,14, 61.CrossRefGoogle Scholar
  61. 61.
    Reist, E. J., Bradford, W. W., Ruhland-Fritsch, B. L. et al. Nucleosides Nucleotides 1994,13, 539.CrossRefGoogle Scholar
  62. 62.
    Huffman, J. H., Sidwell, R. W., Morrison, A. G. et al. Nucleosides Nucleotides 1994, 13, 607.CrossRefGoogle Scholar
  63. 63.
    Ashton, W. W., Canning, L. F., Reynolds, G. F. et al. J. Med. Chem. 1985, 28, 926.CrossRefGoogle Scholar
  64. 64.
    Tolman, R. L., Field, A. K., Karkas, J. D. et al. Biochem. Biophys. Res. Commun. 1985, 128, 3129.CrossRefGoogle Scholar
  65. 65.
    Karkas, J. D., Germershausen, J., Tolman, R. L. et al. Biochim. Biophys. Acta 1987, 911, 127.CrossRefGoogle Scholar
  66. 66.
    Tolman, R. L. in Nucleotide Analogues as Antiviral Agents, Martin, J. C., ed., American Chemical Society, Washington 1989, pp. 35.Google Scholar
  67. 67.
    Tolman, R. L., Field, A. K., Karkas, J. D. et al. Biochem. Biophys. Res. Commun. 1985, 128, 1329.CrossRefGoogle Scholar
  68. 68.
    (a) Harden, M. R., Jarvest, R. L., Bacon, T. H., Boyd, M. R. J. Med. Chem. 1987, 30, 1636. (b) Harden, M. R., Jarvest, R. L. European Patent 0141927A, 1985.CrossRefGoogle Scholar
  69. 69.
    Boyd, M. R., Bacon, T. H., Sutton, D., Cole, M. Antimicrob. Agents Chemother. 1987, 31, 1238.CrossRefGoogle Scholar
  70. 70.
    Boyd, M. R., Bacon, T. H., Sutton, D. Antimicrob. Agents Chemother. 1988, 32, 358.CrossRefGoogle Scholar
  71. 71.
    Vere Hodge, R. A., Perkins, R. M. Antimicrob. Agents Chemother. 1989, 33, 223.CrossRefGoogle Scholar
  72. 72.
    Ilsley, D. D., Lee, S. H., Miller, W. H., Kuchta, R. D. Biochemistry 1995, 34, 2504.CrossRefGoogle Scholar
  73. 73.
    (a) Jarvest, R. L., Barnes, R. D., Earnshaw, D. L. et al. J. Chem. Soc. Perkin Trans 1990 1, 555. (b) Jarvets, R. L., Barnes, R. D., Earnshaw, D. L. et al. J. Chem. Soc. Chem. Commun. 1990, 555.Google Scholar
  74. 74.
    Earnshaw, D. L., Bacon, T. H., Darlison, S. J. et al. Antimicrob. Agents Chemother. 1992, 36, 2147.CrossRefGoogle Scholar
  75. 75.
    Machida, H., Nishitani, M., Watanabe, Y. et al. Microbiol Immunol. 1995, 39, 201.Google Scholar
  76. 76.
    Hasegawa, T., Kurokawa, M., Yukama, T. A. et al. Antiviral Res. 1995, 27, 271.CrossRefGoogle Scholar
  77. 77.
    (a) Vere Hodge, R. A., Sutton, D., Boyd, M. R. et al. Antimicrob. Agents Chemother. 1989, 33, 1765. (b) Harnden, M. R., Jarvest, R. L., Boyd, M. R. et al. J. Med. Chem. 1989,32,1738.CrossRefGoogle Scholar
  78. 78.
    Vere Hodge, R. A., Darlison, S. J., Readshaw, S. A. Chirality 1993,5, 577.CrossRefGoogle Scholar
  79. 79.
    Cirelli, R., Heme, K., McCrary, M. et al. Antiviral Res. 1996, 29, 141.CrossRefGoogle Scholar
  80. 80.
    For reviews of [(phosphonomethoxy)alkyl]purines and-pyrimidines as anti-viral agents: (a) De Clercq, E. Drugs Exp. Clin. Res. 1990, 16, 319. (b) De Clercq, E. in Trends in Drug Research, Claassen, V., ed., Elsevier, Amsterdam 1990, pp. 133. (c) De Clercq, E. Biochem. Pharmacol. 1991, 42, 963. (d) Vortruba, I., Travnicek, M., Rosenberg, I., Otmar, P. Antiviral Res. 1990, 13, 287. (e) De Clercq, E., Holy, A., Rosenberg, I. et al. Nature 1986, 323, 464. (f) Balzarini, J. Verh. K. Acad. Geneeskd. Belg. 1991, 53, 61. (g) Balzarini, J. Adv. Exp. Med. Biol. 1994, 370, 459. (h) De Clercq, E. AIDS Res. Hum. Retroviruses 1992, 8, 119. (i) Naesens, L., Snoeck, R., Andrei, G. et al. Antivir. Chem. Chemother. 1997,8, 1.Google Scholar
  81. 81.
    Cerny, J., Vortruba, I., Vonka, V. et al. Antiviral Res. 1990,13, 253.CrossRefGoogle Scholar
  82. 82.
    Merta, A., Votruba, I., Rosenberg, I. et al. Antiviral Res. 1990,13, 209.CrossRefGoogle Scholar
  83. 83.
    Foster, S. A., Cerny, J., Cheng, Y.-C. J. Biol. Chem. 1991, 266, 238.Google Scholar
  84. 84.
    Aduma, P., Connelly, M. C., Srinivas, R. V., Fridland, A. Mol Pharmacol. 1995,47, 816.Google Scholar
  85. 85.
    (a) Balzarini, J., Naelsens, L., De Clercq, E. Int. J. Cancer 1990, 46, 337. (b) Naesens, L., Balzarini, J., De Clercq, E. Antiviral Res. 1991, 16, 53. (c) Neyts, J., De Clercq, E. J. Med. Virol 1993, 41, 242. (d) Yang, H., Datema, R. Antimicrob. Agents Chemother. 1991, 35, 1596. (e) Kern, E. R., Vogt, P. E. Antiviral Res. 1990, (Suppl. 1), 110. (f) Maudgal, P. C., De Clercq, E., Huyghe, P. Invest. Ophthalmol Visual Sci. 1987, 28, 243. (g) De Clercq, E., Holy, A. Antimicrob. Agents Chemother. 1991, 35, 701. (h) Stals, F.-S., Zeytinoglu, E., Havenith, M., De Clercq, E. Antimicrob. Agents Chemother. 1993, 37, 218. (i) Soike, K. F., Huang, J. L., Zhang, J. Y. et al. Antiviral Res. 1991,16, 17.CrossRefGoogle Scholar
  86. 86.
    (a) Naesens, L., Balzarini, J., De Clercq, E. Drug. Rev. Med. Virol. 1994, 4, 147 (Review). (b) Balzarini, J., Naesens, L., Herdewijn, P. et al. Proc. Natl. Acad. Sci. USA 1989, 86, 332. (c) Gangemi, J. D., Cozens, R. M., De Clercq, E. et al. Antimicrob. Agents Chemother. 1989, 33, 1864. (d) Balzarini, J., Hao, Z., Herdewijn, P. et al. Proc. Natl. Acad. Sci. USA 1991, 88, 1499. (e) Balzarini, J., Perno, C. F., Schols, D., De Clercq, E. Biochem. Biophys. Res. Commun. 1991, 178, 329. (f) Naesens, L., Neyts, J., Balzarini, J. et al. J. Med. Virol. 1993, 39, 167.CrossRefGoogle Scholar
  87. 87.
    Pauwels, R., Balzarini, J., Schols, D. et al. Antimicrob. Agents Chemother. 1988, 32, 1025.CrossRefGoogle Scholar
  88. 88.
    Egberink, H., Borst, M., Niphuis, H. et al. Proc. Natl. Acad. Sci. USA 1990,87, 3087.CrossRefGoogle Scholar
  89. 89.
    Palu, G., Stefanelli, S., Rassu, M. et al. Antiviral Res. 1991, 16, 115.CrossRefGoogle Scholar
  90. 90.
    Votruba, L, Bernaerts, R., Sakuma, T. et al. Mol. Pharmacol 1987, 32, 524.Google Scholar
  91. 91.
    (a) Holy, A., Votruba, I., Merta, A. et al. Antiviral Res. 1990, 13, 295. (b) Robbins, B. L., Connelly, M. C., Marshall, D. R. et al. Mol. Pharmacol. 1995, 74, 391. (c) Gong, Y. F., Marshall, D. R., Srinivas, R. V., Fridland, A. Antimicrob. Agents Chemother. 1994,38,1683.CrossRefGoogle Scholar
  92. 92.
    Balzarini, J., Holy, A., Jindrich, J. et al. Proc. Natl. Acad. Sci. USA 1991, 88, 4961.CrossRefGoogle Scholar
  93. 93.
    Collier, A. C., Coombs, R. W., Nienow, J. et al. in Proceedings of the First National Conference on Human Retroviruses and Related Infections, 1993, Abstr. 563:158.Google Scholar
  94. 94.
    (a) Heijtink, R. A., De Wilde, G. A., Kruining, J. et al. Antivir. Res. 1993, 21, 141. (b) Heijtink, R. A., Kruining, J., De Wilde, G. A. et al. Antimicrob. Agents Chemother. 1994, 38, 2180. (c) Balzarini, J., Kruining, J., Heijtink, R., De Clercq, E. Antivir. Chem. Chemother. 1994, 5, 360. (d) Tsai, C. C, Follis, K. E., Sabo, A. et al. J. Infect. Dis. 1995, 171, 1338. (e) Yokota, T., Mochizuki, S., Konno, K. et al. Nucleic Acids Symp.Ser. 1990,19, 17.CrossRefGoogle Scholar
  95. 95.
    (a) Naesens, L., Balzarini, J., Rosenberg, I. et al. Eur. J. Clin. Microbiol. Infect. Dis. 1989, 8, 1043. (b) Balzarini, J., Naesens, L., Slachmuylders, J. et al. AIDS 1991, 5, 21. (c) Thormar, H., Balzarini, J., Holy, A. et al. Antimicrob. Agents Chemother. 1993, 37, 2540. (d) Hoover, E. A., Ebner, J. P., Zeidner, N. S., Mullins, J. I. Antiviral Res. 1991, 16, 77. (e) Thormar, H., Georgsson, G., Palsson, P. A. et al. Proc. Natl. Acad. Sci. USA 1995, 92, 3283.CrossRefGoogle Scholar
  96. 96.
    Vahlenkamp, T. W., De Ronde, A., Balzarini, J. et al. Antimicrob. Agents Chemother. 1995, 746.Google Scholar
  97. 97.
    (a) Rose, W. C., Crosswell, A. R., Bronson, J. J., Martin, J. C. J. Natl. Cancer Inst. 1990, 82, 510. (b) Otova, B., Sladka, M., Blazek, K. et al. Folia Biol. Prague 1993, 39, 142. (c) Otova, B., Krenova, D., Zidek, Z. et al. Folia Biol. Prague 1993, 39, 311. (d) Balzarini, J., Verstuyf, A., Hatse, S. et al. Int. J. Cancer 1995, 61, 130.CrossRefGoogle Scholar
  98. 98.
    Otova, B., Zidek, Z., Holy, A. et al. In Vivo 1997,11, 163.Google Scholar
  99. 99.
    Vesely, J., Merta, A., Votruba, I. et al. Neoplasma, 1990, 37, 105.Google Scholar
  100. 100.
    Bronson, J. J., Ghazzouli, I., Hitchcock, M. J. M. et al. in 5th International Conference on AIDS, Montreal, Canada 1989, Abstract MCP 74.Google Scholar
  101. 101.
    Starrett, E., Tortolani, D. R., Russel, J. et al. J. Med. Chem. 1994, 37, 1857.CrossRefGoogle Scholar
  102. 102.
    (a) Benzaria, S., Pelicano, H., Johnson, R. et al. J. Med. Chem. 1996, 39, 4958. (b) Alexander, P., Holy, A. Collect. Czech. Chem. Commun. 1994,59, 2127. (c) Périgaud, C, Girardet, J.-L., Gosselin, G., Imbach, J.-L. in Advances in Antiviral Drug Design, De Clercq, E., ed., JAI Press Inc., Greenwich 1996, 2, 147. (d) Jones, R. J., Bischof-berger, N. Antiviral Res. 1995,27, 1.CrossRefGoogle Scholar
  103. 103.
    Srinivas, R. V., Robbins, B. L., Connely, M. C et al. Int. Antiviral News 1994, 2, 53.Google Scholar
  104. 104.
    Alexander, P., Holy, A., Masojidkova, M. Collect. Czech. Chem. Commun. 1994,59,1853.CrossRefGoogle Scholar
  105. 105.
    Glazier, A. Antiviral Res. 1995, 26, A306.CrossRefGoogle Scholar
  106. 106.
    Glazier, A., Buckheit, R., Yanachkova, M. et al. Antiviral Res. 1994, 23 (Suppl. 1), 65.Google Scholar
  107. 107.
    Starrett, J. E., Tortolani, D. R., Hitchock, M. J. M. et al. Antiviral Res. 1992,19, 267.CrossRefGoogle Scholar
  108. 108.
    Puech, F., Gosselin, G., Lefebvre, I. et al. Antiviral Res. 1993, 22, 155.CrossRefGoogle Scholar
  109. 109.
    Naesens, L., Balzarini, J., Bischofberger, N., De Clercq, E. Antimicrob. Agents Chemother. 1996, 40, 22.Google Scholar
  110. 110.
    (a) Srinivas, R. V., Robbins, B. L., Connely, M. C. et al. Antimicrob. Agents Chemother. 1993, 37, 2247. (b) Cundy, K. C., Fishback, J. A., Shaw, J.-P. et al. Pharm. Res. 1994, 11, 839.CrossRefGoogle Scholar
  111. 111.
    (a) Antiviral Agents Bull. 1994, 7, 232. (b) Barditch-Crovo, P. A., Toole, J., Burgee, H. et al. Antiviral Res. 1995, 26, A229.Google Scholar
  112. 112.
    (a) Naesens, L., Neyts, J., Balzarini, J. et al. Nucleosides Nucleotides 1995,14, 767.CrossRefGoogle Scholar
  113. 113.
    Gilson, R. J. C., Chopra, K., Murray-Lyon, L. et al. Hepatology 1996, 24, Pt. 2, 281A, Abstract 620.Google Scholar
  114. 114.
    Lefebvre, I., Perigaud, C., Pompon, A. et al. J. Med. Chem. 1995, 38, 3941.CrossRefGoogle Scholar
  115. 115.
    Perigaud, C., Gosselin, G., Lefebvre, I. et al. Bioorg. Med. Chem. Lett. 1993, 3, 2521.CrossRefGoogle Scholar
  116. 116.
    Perigaud, C., Aubertin, A.-M., Benzaria, S. et al. Biochem. Pharmacol. 1994, 48, 11.CrossRefGoogle Scholar
  117. 117.
    Benzaria, S., Girardet, J.-L., Perigaud, C et al. Nucleic. Acid Symp. Ser. 1994, 31, 129.Google Scholar
  118. 118.
    Girardet, J.-L., Perigaud, C., Aubertin, A.-M. et al. Bioorg. Med. Chem. Lett. 1995, 5, 2981.CrossRefGoogle Scholar
  119. 119.
    (a) Bronson, J. J., Kim, C U., Ghazzouli, I. et al. in Nucleosides Analogues as Antiviral Agents, Martin, J. C., ed., American Chemical Society, Washington 1989, pp. 72. (b) Balzarini, J., Vahlenkamp, T., Egberink, H. et al. Antimicrob. Agents Chemother. 1997,41,611.CrossRefGoogle Scholar
  120. 120.
    Balzarini, J., Holy, A., Jindrich, J. et al. Antimicrob. Agents Chemother. 1993, 37, 332.CrossRefGoogle Scholar
  121. 121.
    Pauwels, R., Balzarini, J., Schols, D. et al. Antimicrob. Agents Chemother. 1988, 32, 1025.CrossRefGoogle Scholar
  122. 122.
    Kreider, J. W., Bulogh, K., Olson, R. O., Martin, J. C. Antiviral Res. 1990,14, 51.CrossRefGoogle Scholar
  123. 123.
    (a) Kim, C U., Luh, B. Y., Martin, J. C. J. Med Chem. 1990, 33, 1797. (b) Kim, C. U., Luh, B. Y., Bronson, J. J. et al. J. Med. Chem. 1990, 33, 1207. (c) Holy, A., Rosenberg, I., Dvorakova, H., De Clercq, E. Nucleosides Nucleotides 1988, 7, 667. (d) De Clercq, E., Sakuma, T., Baba, M. et al. Antiviral Res. 1987, 8, 261. (e) Yu, K.-L., Bronson, J. J., Yang, H. et al. J. Med. Chem. 1992, 35, 2958. (f) ibid. J. Med. Chem. 1993, 36, 2726.CrossRefGoogle Scholar
  124. 124.
    Kim, H.-T., Kim, D.-K., Kim, Y.-W. et al. Antiviral Res. 1995, 28, 243.CrossRefGoogle Scholar
  125. 125.
    (a) Webb, R. R., Wos, J. A., Bronson, J. J., Martin, J. C. Tetrahedron Lett. 1988, 29, 5475. (b) Bronson, J. J., Ghazzouli, I., Hitchcock, J. M. et al. Med. Chem. 1989, 32, 1457.CrossRefGoogle Scholar
  126. 126.
    Holy, A., Rosenberg, I. Collect. Czech. Chem. Commun. 1987, 52, 2775.CrossRefGoogle Scholar
  127. 127.
    Snoeck, R., Sakuma, T., De Clercq, E. et al. Antimicrob. Agents Chemother. 1988, 32, 1839.CrossRefGoogle Scholar
  128. 128.
    (a) Cihlar, T., Chen, M. S. Mol. Pharmacol. 1996, 50, 1502. (b) Ho, H.-T., Woods, K. L., Bronson, J. J. et al. Mol. Pharmacol. 1992, 41, 197.Google Scholar
  129. 129.
    (a) Xiong, X., Smith, J. L., Chen, M. S. Antiviral Res. 1995, 26, A321. (b) Xiong, X., Smith, J. L., Kim, C et al. Biochem. Pharmacol. 1996, 51, 1563.Google Scholar
  130. 130.
    Neyts, J., Snoecks, R., Schols, D. et al. Virology 1990,179, 41.CrossRefGoogle Scholar
  131. 131.
    (a) Lalezari, J. P. J. AIDS Hum. Retrovirol. 1997, 14, (Suppl. 1), S22. (b) Lalezari, J., Kuppermann, B. D. J. AIDS Hum. Retrovirol. 1997,14, (Suppl. 1), S27.Google Scholar
  132. 132.
    Baba, M., Tanaka, H., De Clercq, E. et al. Biochem. Biophys. Res. Commun. 1989, 165, 1375.CrossRefGoogle Scholar
  133. 133.
    Miyasaka, T., Tanaka, H., Baba, M. et al. J. Med. Chem. 1989, 32, 2507.CrossRefGoogle Scholar
  134. 134.
    Pontikis, R., Benhida, R., Aubertin, A.-M. et al. J. Med. Chem. 1997, 40, 1845.CrossRefGoogle Scholar
  135. 135.
    (a) Mellors, J. W., Im, G.-J., Tramontano, E. et al. Mol. Pharmacol. 1993, 43, 11. (b) Balzarini, J., Karlsson, A., De Clercq, E. Mol. Pharmacol. 1993, 44, 694.Google Scholar
  136. 136.
    Ren, J., Esnouf, R., Garman, E. et al. Natl. Struct. Biol. 1995, 2, 293.CrossRefGoogle Scholar
  137. 137.
    Baba, M., Ito, M., Shigeta, S. et al. Antimicrob. Agents Chemother. 191, 35, 1430.CrossRefGoogle Scholar
  138. 138.
    (a) Baba, M., Tanaka, H., Miyasaka, C. et al. Nucleosides Nucleotides 1995, 14, 575. (b) Baba, M., Shigeta, S., Yuasa, S. et al. Antimicrob. Agents Chemother. 1994, 38, 688.CrossRefGoogle Scholar
  139. 139.
    Tanaka, H., Takashima, H., Ubasawa, M. et al. J. Med. Chem. 1995, 38, 2860.CrossRefGoogle Scholar
  140. 140.
    Goudgaon, N. M., Schinazi, R. F. J. Med. Chem. 1991, 34, 3305.CrossRefGoogle Scholar
  141. 141.
    (a) Tanaka, H., Takashima, H., Ubasawa, M. et al. 1992, 35, 4713. (b) Tanaka, H., Baba, M., Saito, S. et al. J. Med. Chem. 1991, 34, 1511. (c) Tanaka, H., Baba, M., Hayakawa, H. et al. J. Med. Chem. 1991, 34, 349.CrossRefGoogle Scholar
  142. 142.
    (a) De Clercq, E. Med. Res. Rev. 1993, 13, 229. (b) Fossey, C., Laduree, D., Robba, M. J. Heterocycl. Chem. 1994, 31, 177. (c) Pan, B.-C., Chen, Z.-H., Piras, G. et al. J. Heterocycl. Chem. 1994, 31, 177. (d) Danel, K.,Larsen, E., Pedersen, E. B. et al. J. Med. Chem. 1996, 39, 2427.CrossRefGoogle Scholar
  143. 143.
    (a) Hayashi, S., Phadtare, S., Zemlicka, J. et al. Proc. Natl. Acad. Sci. USA 1988, 85, 6127. (b) Phadtare, S., Zemlicka, J. J. Am. Chem. Soc. 1989, 111, 5925. (c) Simons, C., Chokekijchai, S., Mitsuya, H., Zemlicka, J. Nucleosides Nucleotides 1994,13, 17790.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • L. A. Agrofoglio
    • 1
  • S. R. Challand
    • 2
  1. 1.Université d’OrléansOrléansFrance
  2. 2.BeckenhamUK

Personalised recommendations